<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03021460</url>
  </required_header>
  <id_info>
    <org_study_id>MC1577</org_study_id>
    <secondary_id>NCI-2017-00079</secondary_id>
    <nct_id>NCT03021460</nct_id>
  </id_info>
  <brief_title>Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery</brief_title>
  <official_title>Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab&#xD;
      in treating patients with stage III-IV melanoma that cannot be removed by surgery.&#xD;
      Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune&#xD;
      system attack the cancer, and may interfere with the ability of tumor cells to grow and&#xD;
      spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Giving pembrolizumab and ibrutinib may work better in treating patients with&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose of ibrutinib in combination with pembrolizumab in&#xD;
      patients with advanced melanoma. (Phase I) II. To estimate the overall response rate treated&#xD;
      at the maximum tolerated dose of ibrutinib in combination with pembrolizumab in patients with&#xD;
      advanced melanoma. (Dose expansion cohort)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and adverse-event profiles of combination of ibrutinib with&#xD;
      pembrolizumab in patients with advanced melanoma.&#xD;
&#xD;
      II. To evaluate the overall response rate (ORR) in patients advanced melanoma receiving&#xD;
      ibrutinib and pembrolizumab.&#xD;
&#xD;
      III. To evaluate the duration of response, progression-free survival (PFS), and overall&#xD;
      survival (OS) in patients with advanced melanoma receiving ibrutinib and pembrolizumab.&#xD;
&#xD;
      IV. To assess the effect of treatment with ibrutinib and pembrolizumab on Th1/Th2 immune&#xD;
      polarity.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To assess the CD8 T cell response to multiple melanoma-associated antigens, and to&#xD;
      correlate CD8 T cell responses with changes in Th1/Th2 immune polarity.&#xD;
&#xD;
      II. To assess changes in plasma cytokines induced by treatment with ibrutinib and&#xD;
      pembrolizumab.&#xD;
&#xD;
      III. To assess the change in potential biomarkers, such as tumor-bound and soluble PD-L1&#xD;
      levels and tumor-infiltrating lymphocytes, that may correlate with treatment responses.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of ibrutinib.&#xD;
&#xD;
      Patients receive ibrutinib orally (PO) daily on days 1-28 of cycle 1 and days 1-21 of cycle 2&#xD;
      and subsequent cycles. Patients also receive pembrolizumab intravenously (IV) over 30 minutes&#xD;
      on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days&#xD;
      and subsequent cycles repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (Phase I)</measure>
    <time_frame>Up to start of second course of treatment</time_frame>
    <description>Will be defined as the highest dose level among those tested where at most one out of 6 patients develops a dose limiting toxicity prior to the start of their second course of treatment. The maximum grade of each type of toxicity will be recorded for each patient. For each toxicity reported by dose level, the percentage of patients developing any degree of that toxicity as well as the percentage of patients developing a severe degree (grade 3 or higher) will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response (dose expansion cohort)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Estimates of tumor response and binomial confidence intervals will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response evaluated according to Response Evaluation Criteria in Solid criteria (RECIST)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A patient whose tumor has met the RECIST criteria for complete response or partial response on two consecutive evaluations at least 8 weeks apart is considered to have had a tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From study entry to the documentation of disease progression, assessed up to 5 years</time_frame>
    <description>Will be examined in an exploratory and hypothesis-generating fashion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From study entry to death due to any cause, assessed up to 5 years</time_frame>
    <description>Will be examined in an exploratory and hypothesis-generating fashion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Stage III Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIA Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIB Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIC Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IV Cutaneous Melanoma AJCC v6 and v7</condition>
  <condition>Unresectable Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment (ibrutinib, pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (ibrutinib, pembrolizumab)</arm_group_label>
    <other_name>BTK Inhibitor PCI-32765</other_name>
    <other_name>CRA-032765</other_name>
    <other_name>Imbruvica</other_name>
    <other_name>PCI-32765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ibrutinib, pembrolizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ibrutinib, pembrolizumab)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PRE-REGISTRATION- INCLUSION CRITERIA&#xD;
&#xD;
          -  Diagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to&#xD;
             local therapy&#xD;
&#xD;
          -  At least one non-nodal lesion considered measurable by Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) criteria (that is, a lesion whose longest diameter can be&#xD;
             accurately measured as &gt;= 1.0 cm with computed tomography [CT] scan, CT component of a&#xD;
             positron emission tomography [PET]/CT, or magnetic resonance imaging [MRI]) or at&#xD;
             least one malignant lymph node is considered measurable by RECIST criteria (that is,&#xD;
             its short axis is &gt;= 1.5 cm when assessed by CT scan)&#xD;
&#xD;
               -  NOTE: tumor lesions in a previously irradiated area are not considered measurable&#xD;
                  disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2&#xD;
&#xD;
          -  Provide informed written consent&#xD;
&#xD;
          -  Patient is willing to undergo treatment and monitoring at the enrolling institution&#xD;
&#xD;
          -  Willing to provide tissue and blood samples for correlative research purposes&#xD;
&#xD;
          -  REGISTRATION- INCLUSION CRITERIA&#xD;
&#xD;
          -  Histologic or cytologic confirmation of unresectable stage III or metastatic melanoma&#xD;
             (stage IV) not amenable to local therapy&#xD;
&#xD;
          -  Only if patient has had previous exposure to anti-PD-1 or anti-PD-L1 therapy:&#xD;
&#xD;
               -  Patient had disease progression on or within 6 months after anti-PD-1/anti-PD-L1&#xD;
                  therapy in the metastatic setting OR&#xD;
&#xD;
               -  Patient had disease progression within 6 months after the last dose of&#xD;
                  adjuvant/neoadjuvant anti-PD-1/anti-PD-L1 treatment&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1000/mm^3 (obtained =&lt; 14 days prior to&#xD;
             registration)&#xD;
&#xD;
          -  Platelet count &gt;= 75,000/mm^3 (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
               -  Criteria must be met without a transfusion =&lt; four weeks prior to registration&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 X upper limit of normal (ULN); if total bilirubin &gt; 1.5 X ULN&#xD;
             then direct bilirubin =&lt; ULN (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase&#xD;
             (alanine transaminase [ALT]) =&lt; 2.5 x ULN OR =&lt; 5 X ULN for patients with liver&#xD;
             metastases (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 X ULN and creatinine clearance (CrCL) &gt;= 30 ml/min per Cockcroft&#xD;
             Gault formula (obtained =&lt; 14 days prior to registration)&#xD;
&#xD;
          -  Patients of childbearing potential only, negative urine pregnancy test done =&lt; 7 days&#xD;
             prior to study registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PRE-REGISTRATION EXCLUSION CRITERIA&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception within the projected duration of the study, starting with the&#xD;
                  screening visit through 120 days after the last dose of study medication;&#xD;
                  adequate contraception is defined as 2 methods of birth control (e.g., hormonal&#xD;
                  contraceptives, intrauterine device, diaphragm with spermicide, cervical cap with&#xD;
                  spermicide, male condoms, or female condom with spermicide) or prior surgical&#xD;
                  sterilization, or abstinence from heterosexual activity&#xD;
&#xD;
          -  Prior treatment with ibrutinib or prior exposure to BTK inhibitors&#xD;
&#xD;
          -  Uveal melanoma&#xD;
&#xD;
          -  Current use of warfarin or other vitamin K antagonists&#xD;
&#xD;
          -  Require continuous treatment with a strong CYP3A inhibitor&#xD;
&#xD;
          -  Currently participating or has participated in a study of an investigational cancer&#xD;
             therapy agent or using an investigational device within 28 days prior to study&#xD;
             registration&#xD;
&#xD;
          -  Live vaccines within 28 days prior to study pre-registration&#xD;
&#xD;
          -  Invasive surgical procedure within 28 days prior to study pre-registration&#xD;
&#xD;
          -  History of clinically severe (e.g., requires chronic immunosuppressive therapy, [e.g.,&#xD;
             cyclosporine A, tacrolimus]) autoimmune disease (e.g., ulcerative colitis, lupus), or&#xD;
             history of organ transplant&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection, active infection with&#xD;
             hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection&#xD;
&#xD;
          -  Gastrointestinal disease that might inhibit ibrutinib absorption (e.g., malabsorption&#xD;
             syndrome, resection of the stomach or a large portion of small bowel, or&#xD;
             partial/complete bowel obstruction), or unable to swallow capsules&#xD;
&#xD;
          -  Active central nervous system metastases and/or carcinomatous meningitis&#xD;
&#xD;
               -  Note: Patients with untreated brain metastasis will be excluded; patients with&#xD;
                  previously treated brain metastases may participate provided they meet the&#xD;
                  following criteria:&#xD;
&#xD;
                    -  Inactive (without evidence of progression which is documented by CT or MRI&#xD;
                       within 90 days prior to registration), AND&#xD;
&#xD;
                    -  On =&lt; 10 mg/day prednisone or equivalent for at least 28 days prior&#xD;
                       pre-registration&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and toxicity of the&#xD;
             prescribed regimens&#xD;
&#xD;
          -  Clinically significant cardiovascular disease such as unstable angina, myocardial&#xD;
             infarction, or acute coronary syndrome within =&lt; 180 days prior to registration,&#xD;
             symptomatic or uncontrolled arrhythmia, congestive heart failure, or any class 3 or 4&#xD;
             cardiac disease as defined by the New York Heart Association Functional Classification&#xD;
&#xD;
          -  Other active malignancy =&lt; 3 years prior to pre-registration; note: if there is a&#xD;
             history of prior malignancy, the patient must not be receiving other specific&#xD;
             treatment for cancer&#xD;
&#xD;
               -  EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix&#xD;
&#xD;
          -  Currently active, clinically significant cardiovascular disease, such as uncontrolled&#xD;
             arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart&#xD;
             Association Functional Classification; or a history of myocardial infarction, unstable&#xD;
             angina, or acute coronary syndrome =&lt; 6 months prior to pre-randomization&#xD;
&#xD;
          -  Known bleeding disorders (von Willebrand's disease or hemophilia)&#xD;
&#xD;
          -  History of ischemic stroke or intracranial hemorrhage =&lt; 180 days prior to&#xD;
             pre-registration&#xD;
&#xD;
          -  Currently active, clinically significant hepatic impairment Child-Pugh class A, B or C&#xD;
             according to the Child Pugh classification&#xD;
&#xD;
          -  Unresolved toxicities from prior anti-cancer therapy, defined as not resolved to&#xD;
             Common Terminology Criteria for Adverse Events (CTCAE, version [v]4.0) grade 0 or 1,&#xD;
             or to the levels dictated in the inclusion/exclusion criteria with the exceptions of&#xD;
             alopecia and peripheral neuropathy&#xD;
&#xD;
          -  REGISTRATION- EXCLUSION&#xD;
&#xD;
          -  Failure to confirm histologically or cytologically unresectable stage III or&#xD;
             metastatic melanoma (stage IV) not amenable to local therapy&#xD;
&#xD;
          -  Prior chemotherapy, immunotherapy, radioactive, or biological cancer therapy&#xD;
             (including monoclonal antibody [mAb]) =&lt; 28 days prior to registration&#xD;
&#xD;
          -  Received a strong cytochrome P450 (CYP) 3A inhibitor =&lt; 7 days prior to registration&#xD;
&#xD;
          -  Concurrent systemic immunosuppressant therapy =&lt; 21 days prior to registration&#xD;
&#xD;
          -  Recent infection requiring systemic antibiotic treatment that was completed =&lt; 14&#xD;
             prior to registration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew S Block</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2017</study_first_posted>
  <last_update_submitted>January 13, 2023</last_update_submitted>
  <last_update_submitted_qc>January 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03021460
org study id: MC1577
secondary id: NCI-2017-00079
nct id: NCT03021460
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab
      in treating patients with stage III-IV melanoma that cannot be removed by surgery.
      Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune
      system attack the cancer, and may interfere with the ability of tumor cells to grow and
      spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed
      for cell growth. Giving pembrolizumab and ibrutinib may work better in treating patients with
      melanoma.
PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose of ibrutinib in combination with pembrolizumab in
      patients with advanced melanoma. (Phase I) II. To estimate the overall response rate treated
      at the maximum tolerated dose of ibrutinib in combination with pembrolizumab in patients with
      advanced melanoma. (Dose expansion cohort)

      SECONDARY OBJECTIVES:

      I. To assess the safety and adverse-event profiles of combination of ibrutinib with
      pembrolizumab in patients with advanced melanoma.

      II. To evaluate the overall response rate (ORR) in patients advanced melanoma receiving
      ibrutinib and pembrolizumab.

      III. To evaluate the duration of response, progression-free survival (PFS), and overall
      survival (OS) in patients with advanced melanoma receiving ibrutinib and pembrolizumab.

      IV. To assess the effect of treatment with ibrutinib and pembrolizumab on Th1/Th2 immune
      polarity.

      EXPLORATORY OBJECTIVES:

      I. To assess the CD8 T cell response to multiple melanoma-associated antigens, and to
      correlate CD8 T cell responses with changes in Th1/Th2 immune polarity.

      II. To assess changes in plasma cytokines induced by treatment with ibrutinib and
      pembrolizumab.

      III. To assess the change in potential biomarkers, such as tumor-bound and soluble PD-L1
      levels and tumor-infiltrating lymphocytes, that may correlate with treatment responses.

      OUTLINE: This is a dose-escalation study of ibrutinib.

      Patients receive ibrutinib orally (PO) daily on days 1-28 of cycle 1 and days 1-21 of cycle 2
      and subsequent cycles. Patients also receive pembrolizumab intravenously (IV) over 30 minutes
      on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days
      and subsequent cycles repeat every 21 days in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 6 months for 5 years.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Maximum tolerated dose (Phase I)
time frame: Up to start of second course of treatment
description: Will be defined as the highest dose level among those tested where at most one out of 6 patients develops a dose limiting toxicity prior to the start of their second course of treatment. The maximum grade of each type of toxicity will be recorded for each patient. For each toxicity reported by dose level, the percentage of patients developing any degree of that toxicity as well as the percentage of patients developing a severe degree (grade 3 or higher) will be determined.
measure: Tumor response (dose expansion cohort)
time frame: Up to 5 years
description: Estimates of tumor response and binomial confidence intervals will be reported.
measure: Tumor response evaluated according to Response Evaluation Criteria in Solid criteria (RECIST)
time frame: Up to 5 years
description: A patient whose tumor has met the RECIST criteria for complete response or partial response on two consecutive evaluations at least 8 weeks apart is considered to have had a tumor response.
measure: Progression-free survival
time frame: From study entry to the documentation of disease progression, assessed up to 5 years
description: Will be examined in an exploratory and hypothesis-generating fashion.
measure: Overall survival
time frame: From study entry to death due to any cause, assessed up to 5 years
description: Will be examined in an exploratory and hypothesis-generating fashion.
arm group label: Treatment (ibrutinib, pembrolizumab)
arm group type: Experimental
description: Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
intervention type: Drug
intervention name: Ibrutinib
description: Given PO
arm group label: Treatment (ibrutinib, pembrolizumab)
other name: BTK Inhibitor PCI-32765
other name: CRA-032765
other name: Imbruvica
other name: PCI-32765
intervention type: Other
intervention name: Laboratory Biomarker Analysis
description: Correlative studies
arm group label: Treatment (ibrutinib, pembrolizumab)
intervention type: Biological
intervention name: Pembrolizumab
description: Given IV
arm group label: Treatment (ibrutinib, pembrolizumab)
other name: Keytruda
other name: Lambrolizumab
other name: MK-3475
other name: SCH 900475
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Matthew S Block
role: Principal Investigator
affiliation: Mayo Clinic in Rochester
facility: 
country: United States
responsible party type: Sponsor
mesh term: Melanoma
mesh term: Skin Neoplasms
mesh term: Pembrolizumab